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Metabolic syndrome (MetS) is a clinical syndrome that consists of visceral obesity, dyslipidemia, hypertension, and impaired
insulin sensitivity. Although individual components of MetS have been implicated in the development of chronic kidney
disease (CKD), few studies have examined the eﬀect of combinations of the components of MetS on the development of
CKD and cardiovascular disease (CVD). The prevalence of MetS is increasing worldwide in both developing and developed
countries, and early detection and treatment of MetS would be a cost-eﬀective strategy for preventing the development of CKD.
Visceral obesity and insulin resistance are two important features of MetS that may be associated with renal damage. Lifestyle
modiﬁcations,includingcaloricrestrictionandexercise,arenecessarytotreatMetS.Initialantihypertensivetherapyshouldconsist
of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. An improved understanding of the mechanism
responsible for the association between MetS and renal damage should be helpful in determining the treatment regimens directed
at cardiovascular and renal protection.
1.Introduction
Chronic kidney disease (CKD) has a major impact on
the quality of life of patients, health services, and society.
CKD is now also widely accepted as a risk factor for
cardiovascular disease (CVD) and mortality [1–3], and
recent reports, including those of observations in Japan,
support this notion [4–6]. The Kidney Early Evaluation
Program (KEEP) screened 6071 eligible persons for CKD
and reported that 16% had a reduced estimated glomerular
ﬁltration rate (eGFR) and that 44% were obese [7]. A
systematic review of 39 studies that included a total of
more than a million patients revealed an increased relative
risk of all-cause mortality in non-dialysis-dependent CKD
patients, and the absolute risk of death appeared to increase
exponentially as renal function diminished [8]. Thus, CKD
is common among persons who have experienced a stroke
and among patients with CVD, diabetes mellitus, and other
medical conditions.
In both the Western world [9] and Japan [10], there has
been an increase in the prevalence of CKD that has paralleled
the increase in prevalence of obesity in recent years. The
World Health Organization (WHO) deﬁnes normal body
weight on the basis of body mass index (BMI) as a BMI
of 18.5–24.9, overweight as a BMI ranging from 25 to
29.9, and obesity as a BMI of 30 or more [11]. Obesity
was demonstrated to be a predictor of the development
of CKD in two large studies of 5897 patients and 11,104
patients, respectively [12, 13]. Analysis of data from the
Second National Health and Nutrition Examination Survey
(NHANESII)intheUnitedStatesidentiﬁedanincreasedrisk
of CKD in persons who were morbidly obese [14].
BMI was found to be associated with an increased risk
of developing end-stage renal disease (ESRD) in men in
a Japanese cohort [15], and a similar positive association
between CKD and obesity was demonstrated among men
in a population-based study in Singapore [16]. Obesity
has not only been suggested to cause renal disease, but it
appears to accelerate its progression. A retrospective cohort
study of 320,252 healthcare-insured participants in northern
California who were followed for 15–35 years revealed that
the rate of ESRD increased in a stepwise manner as BMI
rose [17]. In that study, the age-, sex-, and race-adjusted
rates of ESRD increased from 10 per 100,000 person-years2 Cardiology Research and Practice
among those with normal weight (BMI, 18.5 to 24.9) to
108 per 100,000 among whose BMI was greater than 40.
High BMI is likely to be a risk factor for the progression of
CKD.Metabolic syndrome (MetS)is a clinical syndrome that
consists of visceral obesity, dyslipidemia, hypertension, and
impaired insulin sensitivity.
2. Epidemiology of MetS and CKD
The relationship between MetS and CKD has recently been
examined. Ninomiya et al. performed a slope analysis of
the association between the GFR slope and MetS by using
am u l t i p l er e g r e s s i o nm o d e l[ 18]. The results showed that
the multivariate-adjusted mean value for the GFR slope
decreased signiﬁcantly in subjects with 4 or more MetS
components in comparison with those who had 1 or no
components, and the mean of the GFR slope was also
signiﬁcantly lower in subjects with 3MetS components in
the 60 year and over age group. Chen et al. investigated
the risk of developing CKD, deﬁned by a Modiﬁcation of
Diet in Renal Disease study (MDRD)-eGFR of less than
60mL/min per 1.73m2, in a cohort of the NHANES III
study that included >7800 participants who had normal
renal function at baseline and were followed for >21 years
[19]. The results showed that the multivariate-adjusted odds
ratio (OR) for CKD of the participants with MetS was 2.6 in
relation to participants without MetS, and the OR increased
from 1.89 to 5.85 as the number of components of MetS
that were present increased. Importantly, the relationship
persisted after exclusion of diabetes. They also found a 2-
foldincrease in the risk formicroalbuminuria that correlated
with the number of components of MetS. Palaniappan et al.
demonstrated a higher rate of microalbuminuria in men and
women with MetS than in healthy controls [20]. The cutoﬀ
point of the urinary albumin-to-creatinine ratio varied in
subjects with various CVD risk proﬁles, and even low-
grade albuminuria below the conventional cutoﬀ point for
microalbuminuria was associated with increased prevalence
of CKD [21]. Kurella et al. performed a longitudinal cohort
study and found a higher rate of CKD in MetS even
after adjustment for subsequent development of diabetes
and hypertension, suggesting that MetS is independently
associated with an increased risk for incident CKD in
nondiabeticadults[22].Theseﬁndingssuggestthattheonset
ofrenaldysfunctionmayoccurlongbeforetheappearanceof
hypertension or diabetes in patients with MetS.
3.Possible Role of MetS in
the Development of CKD
In a population of nondiabetic American Indians with a
high prevalence of MetS (38%), MetS was found to be
associated with an increased risk of incident CKD, but no
adjustment for hypertension status was made in that study
[23]. The relationship between MetS and incident CKD
was stronger than among members of the population who
developed diabetes during the followup period, suggesting
that the development of diabetes was a likely mechanism of
the increased risk of CKD associated with MetS. The authors
also reported a 2.6-fold increased prevalence of CKD among
adults with MetS in NHANES III [19].
Microalbuminuria has been described as the earliest
manifestation of MetS-associated kidney damage and dia-
betic nephropathy, and it is associated with insulin resistance
independent of diabetes [24]. MetS is often accompa-
nied by increased plasma renin activity, angiotensinogen,
angiotensin-converting enzyme activity, and angiotensin
II (renin-angiotensin-aldosterone system) and with renal
sympathetic activity. Hyperinsulinemia, insulin resistance,
and increased plasma angiotensin II levels are potent
activators of expression of transforming growth factor-
β1, a ﬁbrogenic cytokine that contributes to glomerular
injury [25]. Microalbuminuria is attributable to augmented
hyperﬁltration, a well-recognized glomerular hemodynamic
change in patients with MetS [26–29].
The mechanisms by which MetS causes and exacer-
bates CKD remain a matter of speculation (Figure 1).
The hallmark of MetS is insulin resistance. Inﬂammatory
mediators, including tumor necrosis factor (TNF)-α,h a v e
been shown to mediate insulin resistance [30]. Adipokines,
including TNF-α,IL-6,andresistin,arecytokinessecretedby
adipose tissue, and their plasma concentrations are elevated
in patients with MetS, whereas their plasma adiponectin
levels are reduced. These ﬁndings may contribute to insulin
resistance, and insulin resistance promotes chronic inﬂam-
mation. Several studies have shown that visceral adipose
tissue is a major source of adipokine secretion in MetS [31].
Adiponectin has been shown to be an adipokine that
has cardiorenal protective properties [32, 33]. Plasma
adiponectin levels are negatively correlated with visceral
fat mass, body weight, blood pressure, insulin resistance,
inﬂammatory markers of MetS, and high triglyceride and
LDL cholesterol levels, and they are positively correlated
with HDL cholesterol levels and weight loss [34]. Hypoad-
iponectinemia is associated with vascular dysfunction and
cardiovasculareventsinMetSpatientswhodonothaveCKD
[35]. Thus, adiponectin may be important in preventing
some of the deleterious eﬀectsthat the chronic inﬂammatory
state exerts on various organs, including the kidney. Becker
et al. found that low adiponectin levels in patients with
mild or moderate renal dysfunction were correlated with
cardiovascular events [36], whereas Menon et al. reported
ﬁnding that all-cause mortality and cardiovascular mortality
were paradoxically higher in patients with stage 3 or 4 CKD
who had high adiponectin levels [37], suggesting that plasma
adiponectin levels are inﬂuenced by renal function. Whether
adiponectin is renoprotective or cardioprotective in CKD
patients with MetS is still unknown.
Activationoftherenin-angiotensin-aldosteronesystemis
commonin patients withMetSdespite sodium retention and
aclearlyincreasedextracellularﬂuidvolume[38,39].Several
mechanisms to explain its activation have been postulated:
(a) hemodynamic alterations, including interference with
renal blood ﬂow [40]; (b) sympathetic stimulation, which is
relatedtohyperleptinemia, andpossibly tohyperinsulinemia
and insulin resistance [41]; (c) synthesis of several proteins
in the renin-angiotensin-aldosterone system by visceral fatCardiology Research and Practice 3
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Figure 1: Hemodynamic consequences of obesity leading to hyperﬁltration and hypertension.
tissue [42]. A review of these mechanisms has shown that
hypertension,increasedglomerularpressure,exacerbationof
proteinuria, induction of intrarenal inﬂammatory cytokines
and growth factors, and apoptosis are some of the dele-
terious eﬀects of angiotensin II on the kidney [43]. In
addition, angiotensin II may play a role in the regulation of
adipokine production in adipose tissue. Since olmesartan, an
angiotensin II type 1 receptor blocker, signiﬁcantly reduced
inﬂammatory cytokines and markers of oxidative stress and
increased adiponectin levels in a mouse model of obesity
[44], angiotensin II may adversely aﬀect the residual renal
function of patients with CKD.
With regard to potential pharmacologic therapies, it is
important to note that aldosterone secretion tends to be
more pronounced in obese African Americans than in obese
American Whites [45]. Obesity and MetS are frequently
associated with increased aldosterone levels and impaired
sodium excretion [46], and this “double hit” of expanded
volume and relative hyperaldosteronism may be particularly
important. Several studies have reported a “mild variant of
primary aldosteronism” in hypertensive African Americans
and that it was even more pronounced in a subgroup
with both obesity and MetS [47–49]. The assertion that
antialdosterone therapy may not beneﬁt certain races is not
basedonsolidevidenceeventhoughtheremaybediﬀerences
between the races in the increase in aldosterone levels.
4. CKD as a Risk Factor for CVD
An independent graded association has been observed
between lower estimated GFR values and increased risk
of death and cardiovascular events in a large community-
based population [3]. Although the initial data linking CKD
and increased risk of CVD were limited and complicated
by multiple confounding variables (Figure 2) ,C K Di sn o w
widely recognized as an independent risk factor for the
developmentofCVD[50].Indeed,studiesoftherelationship
between CKD and CVD have generated impressive results
over the last few years [51]. In many patients with CKD,
the risk of death was found to be greater than the risk
of progression to ESRD [52, 53]. In recent publications
that have evaluated data obtained through the National
Kidney Foundation’s (NKF), KEEP, and NHANES, CKD was
found to be associated with signiﬁcantly increased rates of
myocardial infarction, stroke, and short-term mortality in
comparison with the general population (Figure 3)[ 54].
In studies that stratiﬁed the rates of CVD and all-cause
mortality according to GFR values, graded increases were
seenasGFRdeclineevenafteradjustingforageandcommon
confounders, highlighting the need for eﬀective CVD risk
reduction early in the course of CKD prior to signiﬁcant loss
of renal ﬁltration function [52, 53].
5.Treatment ofCKDAssociatedwithMetS
Each of the components of MetS is capable of independently
causing renal injury and increasing the risk of CKD and
CVD. A number of therapeutic interventions that target
individual components of MetS and associated conditions
may have direct beneﬁts on the kidney and heart. Reduction
of adipose tissue mass can be achieved with preventive
interventions, caloric restriction with or without physical
activity. Lifestyle modiﬁcations are required to treat MetS.
Weightreductioniseﬀectiveinreducingproteinuriainobese
patients [55, 56]. Weight loss also has a protective eﬀect
against progression of CKD to ESRD but may no longer be
indicated once progression to ESRD has occurred, because
renalreplacementtherapyhasaparadoxicaleﬀectonsurvival
[57], and a higher BMI has a beneﬁcial eﬀect on the survival
in ESRD patients. Bariatric surgery is often performed in4 Cardiology Research and Practice
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Figure 2: Complex pathogenesis of chronic kidney disease (CKD) and cardiovascular disease (CVD) [50].
cases of extreme obesity (BMI > 40). Navarro-D´ ıaz et al.
reported a remarkable improvement in glomerular hyper-
ﬁltration following recovery from renal alterations [58].
Exercise training improves various metabolic parameters,
including triglyceride and HDL cholesterol levels, resting
blood pressure and insulin resistance, in patients with MetS
[59], and the improved metabolic proﬁle may reduce risk of
CKD and CVD.
Peroxisome proliferators-activated receptors (PPARs)-
α agonists (the ﬁbrates) [60] and PPAR-γ agonists (the
thiazolidinediones) [61] improve insulin sensitivity, but they
are not without risks in CKD patients. Blockade of the renin-
angiotensin system is likely to be beneﬁcial, but treatment
needs to be individualized according to the degree of renal
dysfunction and whether other comorbidities associated
with visceral obesity are present. The clinical merit of
combination therapy of an angiotensin-converting enzyme
inhibitor and an angiotensin receptor blocker remains a
matter of debate. HMG-CoA reductase inhibitors seem to
be eﬀective in preventing the progression of CKD. Fried et
al. found that eﬀective treatment of dyslipidemia decreased
proteinuria and retarded the progression of CKD in a
meta-analysis [62]. Large randomized controlled trials to
examine the eﬀects of each of these interventions on the
renal function of patients with MetS are needed before any
recommendations can be made.
6. Conclusion andFutureProspects
MetS may be an independent risk factor for CKD and
microalbuminuria in addition to being a risk factor for
CVD and diabetes. Possible mechanisms by which MetS
increases the risk of CKD involve inﬂammation, hemody-
namic eﬀects, and imbalanced adipokine secretion. Cost-
eﬀective strategies to prevent CKD and ESRD that are
feasible for each individual region are needed. However, few
data are available on the beneﬁcial eﬀects of lifestyle and
pharmacological interventions in CKD patients with MetS.
An improved understanding of the mechanism responsible
for the association between MetS and renal damage and
large randomized controlled trials of therapeutic regimens
designed to prevent the onset and progression of CKD
should be helpful in determining which regimen is opti-
mal.
In the next decade, there will be a signiﬁcant need to
conduct randomized controlled trials in order to evaluateCardiology Research and Practice 5
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the impact of the various proposed therapeutic approaches
to MetS. One of the main challenges of such approaches is
that the ideal outcomes of interest of such trials need to be
carefully selected. The overall goal of these approaches to
MetScareistoimprovethequalityoflife.Inlightofthisgoal,
it will be important to monitor multiple relevant outcomes,
such as the incidence and management of CKD and CVD,
together with the well-known complications of MetS.
Insulin resistance, a key mechanism of MetS, is con-
sidered the hallmark of MetS and is believed to be the
underlying reason for the associated systemic metabolic
derangements of hypertension and dyslipidemia, which
are considered fundamental pathogenetic factors in arte-
riosclerosis and may contribute directly to renal injury by
impairing normal hemodynamic processes through multiple
mechanisms [63]. The guidelines of the American Heart
Association recommend lifestyle modiﬁcations including
weight reduction, dietary changes, and physical activity, as
ﬁrst-line therapy for patients with MetS [64].
Initial antihypertensive therapy should consist of an
angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker, unless there are contraindications or
concomitant diseases with compelling indications for
other drugs. Appropriate second-line antihypertensive drugs
includeacalciumchannelblockeroradiuretic.Mostpatients
with MetS will need more than one antihypertensive drug
to achieve the target blood pressure values. Combination
therapy for multiple cardiovascular risk factors is critical to
the successful management of CKD patients with MetS.
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